Abstract P4-21-17: BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer
Cocquyt, VF, Martinez-Mena, CL, Martens, MT, D'Hondt, RG, Graas, M-PL, Evron, E, Fried, G, Ben-Baruch, NE, Dijkstra, AC, Van De Walle, EI
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
Abstract P1-02-07: Discordance for low and intermediate levels (1+ or 2+ by IHC) of HER2 protein expression in the phase III PRESENT trial
Rugo, HS, Melisko, M, Ben-Baruch, NE, Price Hiller, J, Dahkil, S, Sutton, L, Mazanet, R, Mittendorf, E
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article